HIV I infection

This early-stage study tested a new HIV vaccine called VIR-1388 in 93 healthy adults who did not have HIV. The goal was to see if the vaccine is safe and whether it triggers an immune response. Participants received either the vaccine or a placebo, and researchers monitored side …

In sub-Saharan Africa, tuberculosis often causes sepsis in people living with HIV, and many die within days. This phase 3 trial tests two changes to standard care: starting anti-TB therapy right away instead of waiting for test results, and using a higher, sepsis-specific dose in…

This study looks at whether CABENUVA, a long-acting injectable HIV medication, is safe and effective for people with HIV who also have severe kidney impairment, including those on dialysis. Participants receive the drug as monthly or every-2-month injections. The goal is to see h…

This completed early-phase trial tested whether switching HIV medications to doravirine (with emtricitabine and tenofovir alafenamide) could improve cholesterol and reduce early signs of artery hardening compared to staying on integrase inhibitors. Twenty-six adults with well-con…

This study tested whether giving a full 3-month supply of TB preventive medicine directly in the community helps more people finish their treatment compared to standard clinic visits. Researchers enrolled 301 adults in South Africa who were at risk for TB, including those with HI…